These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23641864)

  • 21. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O;
    Int J Urol; 2009 May; 16(5):499-506. PubMed ID: 19389083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial].
    Al-Shukri SH; Pushkar DY; Apolikhin OI; Evdokimov MS; Kogan MI; Krivoborodov GG; Kagan OF; Petrov SB; Poltoratskyi AN; Kuzmin IV; Sharvadze GG
    Urologiia; 2018 Dec; (6):20-25. PubMed ID: 30742373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume.
    Yokoyama O; Homma Y; Yamaguchi O
    Urology; 2013 Sep; 82(3):515-20. PubMed ID: 23876590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscarinic receptors in the bladder: from basic research to therapeutics.
    Hegde SS
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?
    Wu JP; Peng L; Zeng X; Li H; Shen H; Luo DY
    Int Urogynecol J; 2021 May; 32(5):1117-1127. PubMed ID: 32405660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular effects of antimuscarinic agents in overactive bladder.
    Rosa GM; Bauckneht M; Scala C; Tafi E; Leone Roberti Maggiore U; Ferrero S; Brunelli C
    Expert Opin Drug Saf; 2013 Nov; 12(6):815-27. PubMed ID: 23800037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.
    Ohno T; Nakade S; Nakayama K; Kitagawa J; Miyabe H; Konomi T; Miyata Y
    Drug Metab Pharmacokinet; 2008; 23(6):456-63. PubMed ID: 19122340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats.
    Yamazaki T; Muraki Y; Anraku T
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Sep; 384(3):319-29. PubMed ID: 21814879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi T; Yamaguchi O
    Int J Urol; 2008 Sep; 15(9):809-15. PubMed ID: 18637156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland.
    Yoshida A; Kuraoka S; Ito Y; Okura T; Deguchi Y; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
    J Pharmacol Sci; 2014; 124(1):40-6. PubMed ID: 24389821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
    Huang W; Zong H; Zhou X; Zhang Y
    Int Urol Nephrol; 2015 Mar; 47(3):457-64. PubMed ID: 25636812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
    Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
    Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature.
    Masumori N
    Patient Prefer Adherence; 2013; 7():111-20. PubMed ID: 23390360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
    Park C; Park J; Choo MS; Kim JC; Lee JG; Lee JZ; Lee KS; Kim DY; Lee SJ; Seo JT
    Int J Clin Pract; 2014 Feb; 68(2):188-96. PubMed ID: 24373019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with imidafenacin in the management of overactive bladder disorder.
    Takeuchi T; Zaitsu M; Mikami K
    Ther Adv Urol; 2013 Feb; 5(1):43-58. PubMed ID: 23372610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Koide T; Hara R; Fukumoto K; Miyaji Y; Nagai A
    Urol Int; 2013; 90(2):161-7. PubMed ID: 23207959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.